IDEXX Laboratories (IDXX) is a publicly traded Healthcare sector company. As of November 17, 2026, IDXX trades at $685.07 with a market cap of $55.20B and a P/E ratio of 35.57. IDXX moved -1.50% today. Year to date, IDXX is +1.16%; over the trailing twelve months it is +3.16%. Its 52-week range spans $356.14 to $769.98. Analyst consensus is strong buy with an average price target of $745.00. Rallies surfaces IDXX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks hedge fund and 13F ownership for IDXX, including fund holders, share counts, and position changes when data is available.
| Metric | Value |
|---|---|
| Price | $685.07 |
| Market Cap | $55.20B |
| P/E Ratio | 35.57 |
| EPS | $14.33 |
| Dividend Yield | 0.00% |
| 52-Week High | $769.98 |
| 52-Week Low | $356.14 |
| Volume | 273.25K |
| Avg Volume | 0 |
| Revenue (TTM) | $4.55B |
| Net Income | $1.14B |
| Gross Margin | 62.45% |
8 analysts cover IDXX: 0 strong buy, 6 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $745.00.